#	Pagina
attuale pagina	/open-h2020/projects/216603/index.html

Opendata, web and dolomites

CARAMBA SIGNED

SLAMF7-CAR T cells prepared by Sleeping Beauty gene-transfer for immunotherapy of multiple myeloma – a rare hematologic disease

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Outcomes and
results

CARAMBA project word cloud

Explore the words cloud of the CARAMBA project. It provides you a very rough idea of what is the project "CARAMBA" about.

families engineered authorization proprietary designation chimeric antigen advocacy incurable car attractive men confident multiple treatment substantially commercially synthetic edge proposing socioeconomically desirable expressed centres demand immunotherapy technologies clinical received investigators virus patients leukemia dna cells hematologic prepared equally caregivers excellence efficacy women substantial recruitment transfer participation curative indication market unprecedented beauty rapid successful myeloma malignancy therapeutically ensured sleeping gene conduct diseases revolutionary building cutting complete minicircles express safety slamf7 ec group sustainable cell burden validated lymphoma rare sme cd19 breakthrough manufacturing proof mpe highlighted therapy receptor socioeconomic patient free reduces tackle uniformly orphan caramba economically trial medicinal

Project "CARAMBA" data sheet

The following table provides information about the project.

Coordinator	UNIVERSITAETSKLINIKUM WUERZBURG - KLINIKUM DER BAYERISCHEN JULIUS-MAXIMILIANS-UNIVERSITAT Organization address address: JOSEF-SCHNEIDER-STRASSE 2 city: WURZBURG postcode: 97080 website: www.uk-wuerzburg.de contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	Germany [DE]
Project website	http://www.caramba-cart.eu
Total cost	6˙097˙875 €
EC max contribution	6˙097˙875 € (100%)
Programme	1. H2020-EU.3.1.3. (Treating and managing disease)
Code Call	H2020-SC1-2017-Two-Stage-RTD
Funding Scheme	RIA
Starting year	2018
Duration (year-month-day)	from 2018-01-01 to 2022-04-30

Partnership

Take a look of project's partnership.

#	participants	country	role	EC contrib. [€]
1	UNIVERSITAETSKLINIKUM WUERZBURG - KLINIKUM DER BAYERISCHEN JULIUS-MAXIMILIANS-UNIVERSITAT UNIVERSITAETSKLINIKUM WUERZBURG - KLINIKUM DER BAYERISCHEN JULIUS-MAXIMILIANS-UNIVERSITAT Organization address address: JOSEF-SCHNEIDER-STRASSE 2 city: WURZBURG postcode: 97080 website: www.uk-wuerzburg.de contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	DE (WURZBURG)	coordinator	2˙021˙250.00
2	OSPEDALE SAN RAFFAELE SRL OSPEDALE SAN RAFFAELE SRL Organization address address: VIA OLGETTINA 60 city: MILANO postcode: 20132 website: www.hsr.it contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	IT (MILANO)	participant	893˙125.00
3	DRK-BLUTSPENDEDIENST BADEN-WURTTEMBERG-HESSEN GGMBH DRK-BLUTSPENDEDIENST BADEN-WURTTEMBERG-HESSEN GGMBH Organization address address: FRIEDRICH EBERT STRASSE 107 city: MANNHEIM postcode: 68167 website: www.blutspende.de contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	DE (MANNHEIM)	participant	685˙000.00
4	UNIVERSIDAD DE NAVARRA UNIVERSIDAD DE NAVARRA Organization address address: CAMPUS UNIVERSITARIO EDIFICIO CENTRAL city: PAMPLONA postcode: 31080 website: www.unav.es contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	ES (PAMPLONA)	participant	624˙375.00
5	T-CURX GMBH T-CURX GMBH Organization address address: FRIEDRICH-BERGIUS-RING 15 city: WURZBURG postcode: 97076 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	DE (WURZBURG)	participant	503˙750.00
6	CENTRE HOSPITALIER REGIONAL ET UNIVERSITAIRE DE LILLE CENTRE HOSPITALIER REGIONAL ET UNIVERSITAIRE DE LILLE Organization address address: AVENUE OSCAR LAMBRET 2 city: LILLE postcode: 59037 website: http://www.chru-lille.fr/ contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	FR (LILLE)	participant	384˙375.00
7	BUNDESINSTITUT FUR IMPFSTOFFE UND BIOMEDIZINISCHE ARZNEIMITTEL BUNDESINSTITUT FUR IMPFSTOFFE UND BIOMEDIZINISCHE ARZNEIMITTEL Organization address address: PAUL-EHRLICH-STRASSE 51-59 city: LANGEN postcode: 63225 website: www.pei.de contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	DE (LANGEN)	participant	342˙875.00
8	ARTTIC ARTTIC Organization address address: RUE DU DESSOUS DES BERGES 58A city: PARIS postcode: 75013 website: www.arttic.eu contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	FR (PARIS)	participant	327˙500.00
9	NBE-THERAPEUTICS AG NBE-THERAPEUTICS AG Organization address address: HOCHBERGERSTRASSE 60C TECHNOLOGIE PARK BASEL city: BASEL postcode: 4057 website: www.nbe-therapeutics.com contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	CH (BASEL)	participant	200˙000.00
10	MYELOMA PATIENTS EUROPE AISBL MYELOMA PATIENTS EUROPE AISBL Organization address address: RUE DE DAMPREMY 67 BTE 32 city: Charleroi postcode: 6000 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	BE (Charleroi)	participant	115˙625.00

Map

Project objective

CARAMBA is proposing to use the revolutionary CAR-T cell technology to tackle multiple myeloma, a rare and incurable hematologic malignancy. Myeloma is associated with a substantial socioeconomic burden and there is a strong demand by patients, their families and caregivers for a curative myeloma treatment. The CARAMBA investigators will conduct a phase I/II clinical trial of immunotherapy with patient-derived T cells that are engineered to express a synthetic chimeric antigen receptor (CAR) specific for the myeloma antigen SLAMF7. SLAMF7 is uniformly expressed on all myeloma cells in every patient, and SLAMF7 CAR-T cells will be equally effective in women and men. The efficacy and safety of SLAMF7 CAR-T cells has been validated by the coordinator in comprehensive pre-clinical testing which highlighted their unprecedented curative potential. SLAMF7 CAR-T cells have received an orphan designation for the indication multiple myeloma by the EC. The successful conduct, rapid and complete recruitment into the clinical trial is ensured by participation of 4 clinical myeloma centres of excellence in 4 EU member states, and the largest myeloma patient advocacy group in Europe, MPE. The SME partners in CARAMBA are prepared to develop the SLAMF7 CAR product all the way to market authorization. CAR-T cell therapy has been recognized as a ‘Breakthrough Therapy’ and clinical proof-of-concept obtained with CD19 CAR-T cells in leukemia and lymphoma. CARAMBA is building on novel and proprietary, cutting-edge CAR technologies including virus-free Sleeping Beauty CAR gene-transfer from DNA minicircles which substantially reduces the cost of CAR-T cell manufacturing, making it an economically viable and sustainable medicinal product. We are confident, that if funded, CARAMBA will accomplish its objective to establish the role of CAR-T cell therapy as a therapeutically effective, commercially attractive and socioeconomically desirable treatment in myeloma and other rare diseases.

Publications

List of publications.
year	authors and title	journal	last update
2018	Michael Hudecek, ZoltÃ¡n Ivics Non-viral therapeutic cell engineering with the Sleeping Beauty transposon system published pages: 100-108, ISSN: 0959-437X, DOI: 10.1016/j.gde.2018.06.003	Current Opinion in Genetics & Development 52	2019-09-30

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "CARAMBA" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "CARAMBA" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

PREFERABLE (2019)

Project on Exercise for Fatigue Eradication in Advanced Breast cancer to improve quality of life

Read More

MISTRAL (2020)

Microbiome-based stratification of individuals at risk of HIV-1 acquisition, chronic clinical complications,antimicrobial drug resistance,and unresponsiveness to therapeutic HIV-1 vaccination

Read More

TT4CL (2019)

Clinical development of oral oleylphosphocholine as a new drug for the treatment of Old World Cutaneous Leishmaniasis

Read More